TGFB1 and Miyoshi myopathy: These data demonstrate the rapid and effective rejection of the MM tumors by the armored BCMA CAR T-cells, as well as superior expansion and memory differentiation of the armored CAR T cells under the enhanced TGF-β conditions in vivo, as compared to the non-armored B2 CAR T-cells.